Cargando…

Effects of 1α,25-Dihydroxyvitamin D(3) on the Pharmacokinetics of Procainamide and Its Metabolite N-Acetylprocainamide, Organic Cation Transporter Substrates, in Rats with PBPK Modeling Approach

In this study, possible changes in the expression of rat organic cationic transporters (rOCTs) and rat multidrug and toxin extrusion proteins (rMATEs) following treatment with 1α,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) were investigated. Rats received intraperitoneal administrations of 1,25(OH)(2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balla, Anusha, Jeong, Yoo-Seong, Kim, Hyo-Jung, Lee, Yun-Jong, Chung, Suk-Jae, Chae, Yoon-Jee, Maeng, Han-Joo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402143/ https://www.ncbi.nlm.nih.gov/pubmed/34452094 http://dx.doi.org/10.3390/pharmaceutics13081133

Ejemplares similares

Physiologically-Based Pharmacokinetic Modeling for Drug-Drug Interactions of Procainamide and N-Acetylprocainamide with Cimetidine, an Inhibitor of rOCT2 and rMATE1, in Rats
por: Jeong, Yoo-Seong, et al.
Publicado: (2019)

Simultaneous Determination of Procainamide and N-acetylprocainamide in Rat Plasma by Ultra-High-Pressure Liquid Chromatography Coupled with a Diode Array Detector and Its Application to a Pharmacokinetic Study in Rats
por: Balla, Anusha, et al.
Publicado: (2018)

Effects of 1α,25-dihydroxyvitamin D(3) on the pharmacokinetics and biodistribution of ergothioneine, an endogenous organic cation/carnitine transporter 1 substrate, in rats
por: Vo, Dang-Khoa, et al.
Publicado: (2022)

Molecular basis of the different effects of procainamide and N-acetylprocainamide on the maximum upstroke velocity and half-decay time of the cardiac action potential in guinea pig papillary muscle
por: Sigler, W., et al.
Publicado: (2023)

Differential Effects of 1α,25-Dihydroxyvitamin D(3) on the Expressions and Functions of Hepatic CYP and UGT Enzymes and Its Pharmacokinetic Consequences In Vivo
por: Doan, Trang Nguyen Kieu, et al.
Publicado: (2020)

Therapeutic Effects of Procainamide on Endotoxin-Induced Rhabdomyolysis in Rats
por: Shih, Chih-Chin, et al.
Publicado: (2016)

Differential Metabolic Stability of 4α,25- and 4β,25-Dihydroxyvitamin D(3) and Identification of Their Metabolites
por: Mizumoto, Yuka, et al.
Publicado: (2023)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate Using Plateable Human Hepatocytes With Human Plasma Data and PBPK Modeling
por: Mao, Jialin, et al.
Publicado: (2018)

Primary Human Osteoblasts in Response to 25-Hydroxyvitamin D(3), 1,25-Dihydroxyvitamin D(3) and 24R,25-Dihydroxyvitamin D(3)
por: van der Meijden, Karen, et al.
Publicado: (2014)

Combination Therapy of Ivabradine with Procainamide for the Management of Pediatric Postoperative Junctional Ectopic Tachycardia
por: Dasgupta, Soham, et al.
Publicado: (2023)

PBPK Model for Atrazine and Its Chlorotriazine Metabolites in Rat and Human
por: Campbell, Jerry L., et al.
Publicado: (2016)

A compatibility evaluation between the physiologically based pharmacokinetic (PBPK) model and the compartmental PK model using the lumping method with real cases
por: Ryu, Hyo-jeong, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats
por: Cuello, W. S., et al.
Publicado: (2012)

Current Approaches and Techniques in Physiologically Based Pharmacokinetic (PBPK) Modelling of Nanomaterials
por: Utembe, Wells, et al.
Publicado: (2020)

Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug discovery and development
por: Shaik, Abdul Naveed, et al.
Publicado: (2019)

Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients
por: Kovar, Lukas, et al.
Publicado: (2020)

Procainamide Inhibits DNA Methylation and Alleviates Multiple Organ Dysfunction in Rats with Endotoxic Shock
por: Shih, Chih-Chin, et al.
Publicado: (2016)

Procainamide for the Rapid Suppression of Premature Ventricular Contractions: An (Almost) Forgotten Tool in the Cardiologist’s Armamentarium
por: Muser, Daniele, et al.
Publicado: (2021)

THU233 Reduction Of Overutilization Of 1,25-Dihydroxyvitamin D
por: Brown, Jeremy, et al.
Publicado: (2023)

Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug–drug interaction prediction
por: Gill, Jaidip, et al.
Publicado: (2022)

Development of a Human Physiologically Based Pharmacokinetic (PBPK) Toolkit for Environmental Pollutants
por: Ruiz, Patricia, et al.
Publicado: (2011)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Interstrain Variability in Trichloroethylene Metabolism in the Mouse
por: Chiu, Weihsueh A., et al.
Publicado: (2014)

Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates
por: Kovar, Lukas, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Brain Levels of Drug in Rat
por: Sánchez-Dengra, Bárbara, et al.
Publicado: (2021)

Montmorillonite Poly-L-Lactide Microcomposites of Procainamide for controlled drug delivery: In vitro and In vivo evaluation
por: Kevadiya, B. D., et al.
Publicado: (2013)

Oral procainamide as pharmacological treatment of recurrent and refractory ventricular tachyarrhythmias: A single-center experience
por: Toniolo, Mauro, et al.
Publicado: (2021)

Serum 1,25-Dihydroxyvitamin D: An Outcome Prognosticator in Human Sepsis
por: Nguyen, H. Bryant, et al.
Publicado: (2013)

Expression of nephronectin is enhanced by 1α,25‐dihydroxyvitamin D(3)
por: Hiranuma, Katsuhiro, et al.
Publicado: (2016)

Focus on 1,25-Dihydroxyvitamin D3 in the Peripheral Nervous System
por: Faye, Pierre Antoine, et al.
Publicado: (2019)

The Use of 1α,25-Dihydroxyvitamin D(3) as an Anticancer Agent
por: Marcinkowska, Ewa, et al.
Publicado: (2016)

Pharmacokinetics of toxic chemicals in breast milk: use of PBPK models to predict infant exposure.
por: Clewell, Rebecca A, et al.
Publicado: (2002)

The Implications of Using a Physiologically Based Pharmacokinetic (PBPK) Model for Pesticide Risk Assessment
por: Lu, Chensheng, et al.
Publicado: (2010)

Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical Industry
por: Rowland, M
Publicado: (2013)

Physiologically Based Pharmacokinetic (PBPK) Model for Biodistribution of Radiolabeled Peptides in Patients with Neuroendocrine Tumours
por: Gospavic, Radovan, et al.
Publicado: (2016)

Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects
por: Cui, Cheng, et al.
Publicado: (2021)

A Physiologically Based Pharmacokinetic (PBPK) Modeling Framework for Mixtures of Dioxin-like Compounds
por: Liu, Rongrui, et al.
Publicado: (2022)

No major effects of vitamin D(3) (1,25 dihydroxyvitamin D(3)) on absorption and pharmacokinetics of folic acid and fexofenadine in healthy volunteers
por: Kullak-Ublick, Gerd A., et al.
Publicado: (2016)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

In Vivo Imaging of Experimental Melanoma Tumors using the Novel Radiotracer (68)Ga-NODAGA-Procainamide (PCA)
por: Kertész, István, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_68is5c8lrctq5icg3q27elv77c